Skip to main content

Table 1 Parameters for calculation of event rates, costs and QALYs with QIV versus TIV

From: Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong

Parameter Values References
Clinical inputs   
  Influenza vaccine coverage (≥65 years) 39.1% 15
  TIV vaccine effectiveness against influenza B (2001–2010) 0.45-0.75 7-14
  Reduction in TIV influenza B vaccine effectiveness against TIV-unmatched influenza B lineage 30% 6
  Influenza B hospitalization rate (2001–2010) by age group (per 100,000):   1
  65-79 years 1-40.8  
  ≥ 80 years 0-222.1  
  Hong Kong population (2001−2010) by age group:   24
  65-79 years 600,986-665,642  
  ≥ 80 years 146,066-257,966  
  Influenza B lineage in circulation (2001−2010)   1
  Yamagata 5.3%-96.3%  
  Victoria 3.7-94.7%  
  Case-fatality ratio 0.05% 5
  Percent of inpatient cases with ICU admission: 2.4% 4
  Mortality rate of influenza B in ≥65 years inpatient cases 5.9% 1
Utility   
  Utility score for >65 years 0.84 25
  Utility loss   16-22
  Outpatient care 0.40  
  Hospitalization without ICU care 0.50  
  Hospitalization with ICU care 0.62  
  Life expectancy in Hong Kong (years) 83 24
Cost (USD)*   
  Cost of outpatient clinic (per visit) 49 26
  Number of clinic visit for patients without hospitalization 1 Assumption
  Cost of hospitalization without ICU care (per day) 600 26
  Cost of hospitalization with ICU care (per day) 2,949 26
  Length of illness (days)   
  Outpatient care 7 23
  Hospitalization (length of stay) 10.8 4
  Caregiver salary per day 47 24
  Labor force rate 68% 24
  Unemployment rate 3.7% 24
  1. *1 USD =7.8 HKD.
\